OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Gastrobase.it

Search results for "Xalkori"

In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene ( ALK ) have been associated with marked clinical responses to Crizotinib ( Xalkori ), an oral tyrosine kinas ...


Non–small-cell lung cancer ( NSCLC ) harboring the anaplastic lymphoma kinase gene ( ALK ) rearrangement is sensitive to the ALK inhibitor Crizotinib ( Xalkori ), but resistance invariably develops. ...


The efficacy of the ALK inhibitor, Crizotinib ( Xalkori ) as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer ( NSCLC ) is unknown. A ...


Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening or death ( progression free survival, PFS ) by 66% compared to Crizotinib ( Xalk ...